Work

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

Year: 2016

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v128.22.2110.2110

Authors: Irene M. Ghobrial, Michael R. Savona, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, Noopur Raje, Andrzej Jakubowiak, Mihaela Obreja, Jesus G. Berdeja

Institutions: Dana-Farber Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Washington University in St. Louis, Hackensack University Medical Center, University of Maryland, Baltimore, Emory University, Winship Cancer Institute, Harvard University, University of Chicago Medical Center, Amgen (United States), Sarah Cannon

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2913703682

FWCI: 4.484

Cites:

Cited by: 22

Related to: 10